INT8657

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1983
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 12
Total Number 12
Disease Relevance 2.22
Pain Relevance 3.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (DBI) transport (DBI)
Anatomy Link Frequency
lymphocytes 3
pituitary gland 1
DBI (Homo sapiens)
Pain Link Frequency Relevance Heat
GABA receptor 1 100.00 Very High Very High Very High
Analgesic 6 99.36 Very High Very High Very High
opiate 8 99.28 Very High Very High Very High
narcan 5 98.56 Very High Very High Very High
Morphine 4 98.16 Very High Very High Very High
Central grey 5 96.84 Very High Very High Very High
sodium channel 2 94.28 High High
electroacupuncture 5 93.36 High High
antagonist 53 92.76 High High
headache 7 88.32 High High
Disease Link Frequency Relevance Heat
Cancer 21 98.52 Very High Very High Very High
Epstein-barr Virus 8 97.84 Very High Very High Very High
Urological Neuroanatomy 5 96.84 Very High Very High Very High
Headache Disorders 1 88.96 High High
Endometriosis (extended) 8 82.56 Quite High
Pain 1 82.12 Quite High
Reprotox - General 1 3 81.32 Quite High
Liver Cancer 1 74.64 Quite High
Hyperalgesia 2 68.00 Quite High
INFLAMMATION 4 65.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
On the contrary, beta EPd (6-31) inhibited beta EP* binding as effectively as beta EP, thus indicating that beta EP* binding to lymphocytes does not involve the N-terminal region of beta EP. 2 x 10(7)/ml freshly isolated lymphocytes bound 1.53 +/- 75%, whereas 2 x 10(6)/ml transformed lymphocytes bound 1.64 +/- 0.75% (mean +/- SD) beta EP* at tracer concentration.
EP Binding (binding) of in lymphocytes
1) Confidence 0.42 Published 1989 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 2550003 Disease Relevance 0.15 Pain Relevance 0.23
Peptides representing amino-acid sequences 1-5, 1-16 and 1-17 of beta EP did not inhibit beta EP binding, neither did the opiates compounds Naloxone, Morphine, Bremazocine and Ethylketocyclazocine.
EP Binding (binding) of associated with narcan, opiate and morphine
2) Confidence 0.31 Published 1989 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 2550003 Disease Relevance 0.14 Pain Relevance 0.25
On the contrary, beta EPd (6-31) inhibited beta EP* binding as effectively as beta EP, thus indicating that beta EP* binding to lymphocytes does not involve the N-terminal region of beta EP. 2 x 10(7)/ml freshly isolated lymphocytes bound 1.53 +/- 75%, whereas 2 x 10(6)/ml transformed lymphocytes bound 1.64 +/- 0.75% (mean +/- SD) beta EP* at tracer concentration.
EP Binding (binding) of in lymphocytes
3) Confidence 0.31 Published 1989 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 2550003 Disease Relevance 0.15 Pain Relevance 0.24
On the contrary, beta EPd (6-31) inhibited beta EP* binding as effectively as beta EP, thus indicating that beta EP* binding to lymphocytes does not involve the N-terminal region of beta EP. 2 x 10(7)/ml freshly isolated lymphocytes bound 1.53 +/- 75%, whereas 2 x 10(6)/ml transformed lymphocytes bound 1.64 +/- 0.75% (mean +/- SD) beta EP* at tracer concentration.
EP Binding (bound) of in lymphocytes
4) Confidence 0.31 Published 1989 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 2550003 Disease Relevance 0.16 Pain Relevance 0.21
In the beta-LPH IRMA, antibody 6B2, which recognizes an epitope common to beta-LPH and beta-EP, is radiolabelled and paired with solid-phase antibody 5C11 which recognizes beta-LPH 39-56.
beta-EP Binding (recognizes) of
5) Confidence 0.24 Published 1993 Journal Clin. Endocrinol. (Oxf) Section Body Doc Link 8287571 Disease Relevance 0 Pain Relevance 0
MEASUREMENTS: In the beta-EP IRMA, antibody 6B2, specific for beta-EP 18-27, is radiolabelled and antibody 2E10, recognizing beta-EP 1-5, is coupled to Sephacryl S-300 as solid phase.
beta-EP Binding (recognizing) of
6) Confidence 0.21 Published 1993 Journal Clin. Endocrinol. (Oxf) Section Body Doc Link 8287571 Disease Relevance 0 Pain Relevance 0
Ac beta-EP is present in human fetal and adult pituitary gland and cross-reacts in all available beta-EP assays.
beta-EP Binding (cross-reacts) of in pituitary gland
7) Confidence 0.18 Published 1992 Journal Brain Res. Section Abstract Doc Link 1511339 Disease Relevance 0.15 Pain Relevance 0.29
In vitro, CJ-023,423 inhibits [(3)H]PGE(2) binding to both human and rat EP(4) receptors with K(i) of 13 +/- 4 and 20 +/- 1 nM, respectively.
EP Binding (binding) of
8) Confidence 0.17 Published 2007 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 17495127 Disease Relevance 0.26 Pain Relevance 0.47
Two antisera (HO and UA) were raised in rabbits against human beta-EP, each of which recognized human, porcine, bovine, ovine, camel and rat beta-EP, the only difference being that HO recognized rabbit beta-EP while UA did not.
beta-EP Binding (recognized) of
9) Confidence 0.16 Published 1983 Journal Int. J. Neurosci. Section Abstract Doc Link 6305863 Disease Relevance 0.35 Pain Relevance 0.75
Using radioligand binding assays and/or 36Cl- uptake studies, no interaction of ibogaine or harmaline with the GABA receptor-ionophore was found.
GABA receptor-ionophore Neg (no) Binding (interaction) of associated with gaba receptor
10) Confidence 0.08 Published 1992 Journal Brain Res. Section Abstract Doc Link 1377086 Disease Relevance 0 Pain Relevance 0.43
In this pathway, the Translocator Protein (TSPO) [17], which resides in the outer mitochondrial membrane where it associates with the acyl-CoA binding protein DBI (diazepam binding inhibitor), is a crucial partner in the regulation of AA levels within the mitochondrion, from where it is exported for further conversion to eicosanoid products [16], [17].
acyl-CoA binding protein DBI Binding (associates) of
11) Confidence 0.07 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2978721 Disease Relevance 0.31 Pain Relevance 0
We and others’ have shown that PGE2–EP receptor interaction can down regulate the expression of tumour suppressor genes (Sales et al., 2004c), increase cellular growth, migration and invasiveness (Sheng et al., 2001) and promote angiogenesis in in vitro and in vivo model systems (Watanabe et al., 2000; Sonoshita et al., 2001; Seno et al., 2002; Buchanan et al., 2003; Fujino et al., 2003; Sales et al., 2004a).
EP Binding (interaction) of associated with cancer
12) Confidence 0.01 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0.56 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox